| 注册
首页|期刊导航|山东医药|乳腺癌组织中CD68、VEGF的表达变化及意义

乳腺癌组织中CD68、VEGF的表达变化及意义

阎红琳 吴昊 高利昆 饶洁 袁静萍

山东医药2017,Vol.57Issue(45):9-12,4.
山东医药2017,Vol.57Issue(45):9-12,4.DOI:10.3969/j.issn.1002-266X.2017.45.003

乳腺癌组织中CD68、VEGF的表达变化及意义

Expression and clinical significance of CD68 and VEGF in breast cancer tissues

阎红琳 1吴昊 1高利昆 1饶洁 1袁静萍1

作者信息

  • 1. 武汉大学人民医院,武汉430060
  • 折叠

摘要

Abstract

Objective To investigate the expression and clinical significance of CD68 and vascular endothelial growth factor (VEGF)in breast cancer tissues. Methods Immunohistochemistry was used to detect the expression of CD68 and VEGF in 230 cases of breast cancer tissues and the corresponding adjacent tissues. The relationship of the expression of two proteins with the clinicopathological parameters and the recurrence of breast cancer was analyzed. Meanwhile,the correla-tion between the two proteins was also analyzed. Results The positive rates of CD68 and VEGF in the breast cancer tis-sues were significantly higher than those in the adjacent tissues (both P < 0. 01). The positive rate of CD68 protein in the breast cancer was closely related to the clinical stage,lymph node metastasis,and ER status of breast cancer patients (P <0. 05). The positive rate of VEGF protein in the breast cancer was closely related to the ER status of breast cancer patients (P < 0. 05). The positive rates of CD68 and VEGF proteins in the recurrent patients were significantly higher than those in the non recurrent patients (both P < 0. 05). The expression of CD68 protein was positively correlated with the expression of VEGF (r s = 0. 397,P < 0. 01). Conclusion The expression of CD68 protein and VEGF protein increase in the breast cancer tissues,and they may be involved in the occurrence,development,and recurrence of breast cancer.

关键词

乳腺癌/CD68/血管内皮生长因子/肿瘤微环境

Key words

breast carcinoma/CD68/vascular endothelial growth factor/tumor microenvironment

分类

医药卫生

引用本文复制引用

阎红琳,吴昊,高利昆,饶洁,袁静萍..乳腺癌组织中CD68、VEGF的表达变化及意义[J].山东医药,2017,57(45):9-12,4.

基金项目

国家自然科学基金资助项目(31600866). (31600866)

山东医药

OACSTPCD

1002-266X

访问量0
|
下载量0
段落导航相关论文